| Dienst | Title | Status | Verantwoordelijke | Verantwoordelijke studiecoördinatoren |
|---|---|---|---|---|
| Gastro-enterologie | NATIV3: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis | Recruiting | Prof. Dr. Schouten | Anske Van Den Abbeele: anske.vandenabbeele@vitaz.be Lise Vermeir: lise.vermeir@vitaz.be |
| Gastro-enterologie | TAK-062-2001: A Phase 2, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Free Diet | Recruiting | Dr. Holvoet | Anske Van Den Abbeele: anske.vandenabbeele@vitaz.be Lise Vermeir: lise.vermeir@vitaz.be |
| Gastro-enterologie | M21-446: A single-arm, open-label study to evaluate the efficacy and safety of ABBV-668 in subjects with moderate to severe ulcerative colitis | Recruiting | Dr. Holvoet | Anske Van Den Abbeele: anske.vandenabbeele@vitaz.be Lise Vermeir: lise.vermeir@vitaz.be |
| Gastro-enterologie | SOPRANO: Prevention of postoperative endoscopic recurrence with endoscopy-driven versus systematic biological therapy: a randomized, multicentre, parallel group pragmatic non-inferiority trial in adult patients with Crohn’s disease undergoing an ileocolonic resection with ileocolonic anastomosis | Recruiting | Dr. Holvoet | Anske Van Den Abbeele: anske.vandenabbeele@vitaz.be Lise Vermeir: lise.vermeir@vitaz.be |
| Gastro-enterologie | POMEROL:Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation | In start-up | Dr. Holvoet | Anske Van Den Abbeele: anske.vandenabbeele@vitaz.be Lise Vermeir: lise.vermeir@vitaz.be |
| Gastro-enterologie | HYRISS: A multicenter, international, prospective, non-interventional, observational study, to assess treatment retention of an adalimumab biosimilar (Hyrimoz®) in IBD patients in real life setting | Recruiting | Dr. Holvoet | Anske Van Den Abbeele: anske.vandenabbeele@vitaz.be Lise Vermeir: lise.vermeir@vitaz.be |
| Gastro-enterologie | M23-703: A Multicenter, Randomized study to Evaluate the safety and Efficacy of Lutikizumab for lnduction and Maintenance Therapy in subjects with Moderately to severely Active Ulcerative colitis | In start-up | Dr. Holvoet | Anske Van Den Abbeele: anske.vandenabbeele@vitaz.be Lise Vermeir: lise.vermeir@vitaz.be |
| Gastro-enterologie | Vectors: An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients with Moderately to Severely Active Crohn’s Disease | In start-up | Dr. Holvoet | Anske Van Den Abbeele: anske.vandenabbeele@vitaz.be Lise Vermeir: lise.vermeir@vitaz.be |
| Gastro-enterologie | AMARETTO: Subcutaneous infliximab after a previous intravenous dose optimization | Recruiting | Dr. Holvoet | Anske Van Den Abbeele: anske.vandenabbeele@vitaz.be Lise Vermeir: lise.vermeir@vitaz.be |
| Gastro-enterologie | CRYOPEN: Efficacy of cryotherapy by N20 (CryoPen®) in acute and chronic anal fissures | Recruiting | Dr. Ruymbeke | Anske Van Den Abbeele: anske.vandenabbeele@vitaz.be Lise Vermeir: lise.vermeir@vitaz.be |
| Neurochirurgie | SABR-MESCC: Separation surgery followed by Stereotactic Ablative Body Radiotherapy versus Stereotactic Ablative Body Radiotherapy alone for spinal metastases invading the spinal canal: a randomised, non-inferiority trial (SABR-MESCC) | Recruiting | Prof. Dr. Van De Kelft | Sophie Traen: sophie.traen@vitaz.be |
| Urologie | Thunder: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers | Recruiting | Dr. De Troyer | Sophie Traen: sophie.traen@vitaz.be |
| Urologie | ProBio: An outcome-adaptive and randomized multi-arm biomarker driven study in patients with metastatic castrate resistant prostate cancer (mCRPC) | Recruiting | Dr. De Troyer | Sophie Traen: sophie.traen@vitaz.be |
| Urologie | Moonrise: TAR-210 Versus Single Agent Intravesical Chemotherapy in Participants With FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) | Recruiting | Dr. De Troyer | Sophie Traen: sophie.traen@vitaz.be |
| Psychiatrie | VENTURA5: A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia | In start-up | Dr. De Weirdt | Sophie Traen: sophie.traen@vitaz.be |
| Pediatrie | RSV-Comnet-III: Disease Burden of RSV in Young Children in Primary Care | Recruiting | Dr. Vanlede | Anske Van Den Abbeele: anske.vandenabbeele@vitaz.be |
| Cardiologie | SCAD: A registry of Spontaneous coronary artery dissection (SCAD) | Recruiting | Dr. Voet | Lise Vermeir: lise.vermeir@vitaz.be |
| Cardiologie | CARDURION-1: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction | in start-up | Dr. Delens | Lise Vermeir: lise.vermeir@vitaz.be |
| Cardiologie | CARDURION-2: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction | in start-up | Dr. Delens | Lise Vermeir: lise.vermeir@vitaz.be |
| Neurologie | OCEANIC STROKE: A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA | Recruiting | Dr. Siau | Lise Vermeir: lise.vermeir@vitaz.be |
| Pneumologie | PACIFIC- 8: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8) | Recruiting | Dr. Deschepper | Kirsten Van Camp: kirsten.vancamp@vitaz.be Aurelie De Vos: aurelie.devos@vitaz.be |
| Pneumologie | SAFFRON: A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON) | Recruiting | Dr. Van De Kerckhove | Kirsten Van Camp: kirsten.vancamp@vitaz.be Aurelie De Vos: aurelie.devos@vitaz.be |
| Pneumologie | TROPION-LUNG-07: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) | Recruiting | Dr. Deschepper | Kirsten Van Camp: kirsten.vancamp@vitaz.be Aurelie De Vos: aurelie.devos@vitaz.be |
| Pneumologie | TROPION-LUNG-08: A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08) (Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations) | Recruiting | Dr. Deschepper | Kirsten Van Camp: kirsten.vancamp@vitaz.be Aurelie De Vos: aurelie.devos@vitaz.be |
| Pneumologie | MOMENT: Disease Registry on Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Skipping Alterations MOMENT (Met nOn sMall cEll caNcer regisTry) | Recruiting | Dr. Deschepper | Kirsten Van Camp: kirsten.vancamp@vitaz.be Aurelie De Vos: aurelie.devos@vitaz.be |
| Pneumologie | IMMUNO-MESODEC: Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid malignant pleural mesothelioma | Recruiting | Dr. Deschepper | Kirsten Van Camp: kirsten.vancamp@vitaz.be Aurelie De Vos: aurelie.devos@vitaz.be |
| Pneumologie | V940-002:A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer | In start-up | Dr. Deschepper | Kirsten Van Camp: kirsten.vancamp@vitaz.be Aurelie De Vos: aurelie.devos@vitaz.be |
| Pneumologie | MK2870-019: A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stage II to IIIB (N2) NSCLC for Participants not Achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum based Doublet Chemotherapy Followed by Surgery | In start-up | Dr. Deschepper | Kirsten Van Camp: kirsten.vancamp@vitaz.be Aurelie De Vos: aurelie.devos@vitaz.be |
| Pneumologie | PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors | In start-up | Dr. Deschepper | Kirsten Van Camp: kirsten.vancamp@vitaz.be Aurelie De Vos: aurelie.devos@vitaz.be |
| Pneumologie | eVOLVE-Meso: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma | Recruiting | Dr. Deschepper | Kirsten Van Camp: kirsten.vancamp@vitaz.be Aurelie De Vos: aurelie.devos@vitaz.be |
| Pneumologie | M18-868: Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer | In start-up | Dr. Deschepper | Kirsten Van Camp: kirsten.vancamp@vitaz.be Aurelie De Vos: aurelie.devos@vitaz.be |
| Pneumologie | BO45217: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB VERSUS SOTORASIB OR ADAGRASIB IN PATIENTS WITH PREVIOUSLY TREATED KRAS G12C-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | In start-up | Dr. Deschepper | Kirsten Van Camp: kirsten.vancamp@vitaz.be Aurelie De Vos: aurelie.devos@vitaz.be |
| Pijnkliniek | BONS:Bilateral Occipital Nerve Field Stimulation for the prophylactic treatment of Difficult-to-treat Chronic Cluster Headache | In start-up | Prof. Dr. Van Buyten | Marieke Devos: marieke.devos@vitaz.be |
| Pijnkliniek | ANKERSTIM: Physician initiated database ‘Custom ONS Lead Model 09078’ van Medtronic | Recruiting | Prof. Dr. Van Buyten | Marieke Devos: marieke.devos@vitaz.be |
| Pijnkliniek | DETECT: Differential targEt mulTiplexEd spinal Cord stimulation: a multicenter cohorT study | recruiting | Prof. Dr. Van Buyten | Marieke Devos: marieke.devos@vitaz.be |
| Pijnkliniek | OPERA: Objectifying performance assessments and personalized rehabilitation trajectories to improve return to work in patients with Persistent Spinal Pain Syndrome Type II: a randomized controlled trial. | Recruiting | Prof. Dr. Van Buyten | Marieke Devos: marieke.devos@vitaz.be |
| Pijnkliniek | Product Surveillance Registry (PSR) NEUROLOGY PSTM EMEA INCEPTIV™ cohort | In start-up | Dr. Smet | Marieke Devos: marieke.devos@vitaz.be |
| Pijnkliniek | EU-DETECT: Open and closed loop Differential Target Multiplexed spinal cord stimulation in patients with persistent spinal pain syndrome type II: a European study protocol for a 12-month multicenter cohort study (EU-DETECT) | In start-up | Dr. Smet | Marieke Devos: marieke.devos@vitaz.be |
| Reumatologie | SPEAK: SPONDYLOARTHRITIS (PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS) PATIENT-CENTERED EXPERIENCE INITIATING BIMEKIZUMAB IN ROUTINE CLINICAL PRACTICE: A MULTICOUNTRY, PROSPECTIVE, OBSERVATIONAL STUDY | In start-up | Dr. De Wilde | Lise Vermeir: lise.vermeir@vitaz.be |
| Oncologie - borstkanker | EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor | Recruiting | Dr. Deleu | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Oncologie - borstkanker | EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence | Recruiting | Dr. Deleu | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Oncologie - borstkanker | TROPION-BREAST-03: A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | Recruiting | Dr. Deleu | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Oncologie - borstkanker | VIKTORIA-1 :A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy | Recruiting | Dr. Everaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Oncologie - borstkanker | Destiny Breast Respond: A prospective, non-interventional study (NIS) with trastuzumab deruxtecan for patients with HER2-low expressing unresectable and/or metastatic breast cancer accompanied by a disease registry of patients treated with conventional chemotherapy | in start-up | Dr. Deleu | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Oncologie - borstkanker | ELEVATE: A Phase 1b/2, Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer | Recruiting | Prof. Dr. Kruse | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Digestieve oncologie | CODEBREAK-301: A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus Investigator’s Choice Chemotherapy (FOLFOX or FOLFIRI) with or without Bevacizumab-awwb for Treatment-naïve Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation | In start-up | Dr. Dedecker | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Digestieve oncologie | FOLICOLOR: Following therapy response through liquid biopsy in metastatic colorectal cancer patients | recruiting | Dr. Gorleer | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Digestieve oncologie | DNET: Digestive Neuro-Endocrine Tumors Registry: An epidemiological and medical data collection of patients suffering from Digestive NeuroEndocrine Tumors via an electronic registry | Recruiting | Dr. Lybaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Digestieve oncologie | QUALINET: Patient-reported outcomes in neuroendocrine neoplasms: a prospective quality of life and quality of care study within NETwerk | Recruiting | Dr. Lybaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Digestieve oncologie | PERFORMANCE: Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer: the role of diffusion weighted magnetic resonance imaging, radiomics and liquid biopsy | Recruiting | Dr. Lybaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Digestieve oncologie | SHAPERS: Efficacy and safety of short-course radiotherapy (SCRT) versus total neoadjuvant therapy in older patients with locally advanced rectal cancer: a multicentre, open-label, randomised pragmatic clinical trial | Recruiting | Dr. Lybaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Digestieve oncologie | SAUNA: Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients— The SAUNA trial | Recruiting | Dr. Lybaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Digestieve oncologie | COLLECT-NET: Collection of liquid biopsy samples of patients with neuroendocrine neoplasms | In start-up | Dr. Lybaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Digestieve oncologie | ALLIES: Muscle mass in patients with colorectal or lung cancer when receiving a n-3 PUFA and leucine enriched high protein and high energy oral nutritional supplement during anti-cancer treatment | In start-up | Dr. Lybaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Digestieve oncologie | Retrospective study on outcome and toxicity of treatments for cholangiocarcinoma in Belgium with a special emphasis on Pemazyre” | in start-up | Dr. Lybaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Digestieve oncologie | LIQUID-NET: A prospective, multicentric, proof-of-concept study to evaluate the value of circulating tumour DNA in follow-up of patients with an advanced gastroenteropancreatic or lung neuroendocrine tumour under everolimus ± somatostatin analogues | Recruiting | Dr. Lybaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Oncologie - Dermatologie | Retrospectieve evaluatie van de werkzaamheid en veiligheid van Cemiplimab voor gevorder cutaan squameus celcarcinoma binnen het Belgisch early access programma, | in start-up | Prof. Dr. Kruse | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Oncologie - melanoma | REGENERON-2: A Phase 3 Trial of Fianlimab (Anti-Lag-3) And Cemiplimab Versus Pembrolizumab in the Adjuvant Setting In Patients With Completely Resected High-Risk Melanoma | Recruiting | Dr. Deleu | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Oncologie - melanoma | REGENERON-1: A PHASE 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or metastatic Melanoma: | Recruiting | Dr. Deleu | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Oncologie - hoofd-hals tumoren | AVEO: Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma | In start-up | Dr. Lybaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Oncologie - hoofd-hals tumoren | STELLAR: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF ZANZALINTINIB (XL092) IN COMBINATION WITH PEMBROLIZUMAB VS PEMBROLIZUMAB IN THE FIRST-LINE TREATMENT OF SUBJECTS WITH PD-L1 POSITIVE RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA | Recruiting | Dr. Lybaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Oncologie - hoofd-hals tumoren | PROLONG: Pembrolizumab and Radiotherapy for OLigometastatic squamous cell carcinoma of the head and Neck: a randomized phase III study | In start-up | Dr. Lybaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Uro-oncologie | CORPORA: CheckpOint inhibition in advanced uRothelial carcinoma: PredictiOn of response through RNA profiling (CORPORA) | Recruiting | Dr. Everaert | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Hematologie | LOXO-BTK-20030: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314) | Recruiting | Prof. Dr. Van Hende | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Hematologie | CA057-001: A Phase 3, Randomized, Multicenter, Open-Label Study, Comparing CC-92480, Bortezomib and Dexamethasone (480Vd), with Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) | Recruiting | Dr. Vande Broek | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Hematologie | GCT3013-06: A Randomized, Open-Label, Multicenter, Global, Phase 2 Trial to Assess the Efficacy and Safety of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) Plus Lenalidomide or Epcoritamab Alone as First-line Therapy in Anthracycline Ineligible Subjects With Diffuse Large B-cell Lymphoma | recruiting | Prof. Dr. Van Hende | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Hematologie | Monumental-06: A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide | recruiting | Dr. Vande Broek | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Hematologie | OLYMPIA 2: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETYOF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, COMBINED WITH CHEMOTHERAPY VERSUS RITUXIMAB COMBINED WITH CHEMOTHERAPY IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA | recruiting | Prof. Dr. Van Hende | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
| Oncologie | REMOTE: Targeting Fear of Cancer Recurrence in Cancer Survivors: a multicentre randomized controlled trial to evaluate Internet-Based Emotional Freedom Techniques and Internet-Based Mindfulness Meditation as intervention strategies | In start-up | Dr. Lamot | Veerle De Corte: veerle.decorte@vitaz.be Veerle De Hauwere: veerle.dehauwere@vitaz.be Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be Jenas Stevenheydens: jenas.stevenheydens@vitaz.be Isabel De Brabander: isabel.debrabander@vitaz.be |
